$NVDA NEWS Nvidia stock hits another record as Wall Street stays bullish NasdaqGS - Nasdaq Real Time Price ? USD Replimune Group, Inc. (REPL) Follow Compare 11.35 -0.18 (-1.56%) At close: 4:00 PM EDT 11.35 0.00 (0.00%) After hours: 4:02 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Replimune Announces Inducement Grants Under Nasdaq?Listing Rule 5635(c)(4) WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 9 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 8,870 GlobeNewswire ? 12 days ago REPL -1.56% Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 192,770 shares in Replimune Group Inc (NASDAQ:REPL), a clinical-stage biotechnology company. This move reduced Morgan Stanley's holding by 11.11%, leaving the firm with a total of 1,542,884 shares. Despite the reduction, Morgan Stanley maintains a 2.30% position in REPL, reflecting a strategic adjustment rather than a complete exit. GuruFocus.com ? 13 days ago REPL -1.56% MS-PQ Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$23.01 Replimune... Simply Wall St. ? 19 days ago REPL -1.56% Replimune to Present at Two Upcoming Investor Conferences WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO 2024 Oncology SummitDate: Tuesday, October 8, 2024 3rd Annual Roth Healthcare Opportunities Conference Date: Wednesday, October 9, 2024 About Replimune Replimune Group, GlobeNewswire ? 20 days ago REPL -1.56% Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1 Injected and non-injected lesions responded with similar frequency, depth, duration and kinetics WOBURN, Mass., Sept. 15, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announce GlobeNewswire ? last month REPL -1.56% Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 Aligned with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanomaWOBURN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced it has completed a successful pre-Biologics License Application (pre-BLA) meeting with the U.S. Food and Drug Administration (FDA) that supports the Company’s plans to submit a BLA for RP1 (vusolimogene oderpar GlobeNewswire ? last month REPL -1.56% Stockholders Vote to Elect Madhavan Balachandran to Board of Directors WOBURN, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Madhavan (Madhu) Balachandran was elected to Replimune’s Board of Directors at the Company’s annual meeting of stockholders. “We are thrilled to welcome Madhu to Replimune’s Board of Directors,” said Sushil Patel, Ph.D., Chief Executive Officer of Replimune. “Madhu is an accomp GlobeNewswire ? last month REPL -1.56% Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona. Presentation Details: Title: Primary ef GlobeNewswire ? last month REPL -1.56% Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy Replimune has announced the first patient in the Phase III melanoma trial with its lead immunotherapy RP1 or vusolimogene oderparepvec has been dosed and randomised. The IGNYTE-3 study (NCT06264180) will investigate the use of RP1 plus Bristol Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) for patients with advanced melanoma who have progressed on anti-PD1 and anti-CTLA-4… Pharmaceutical Technology ? 2 months ago REPL -1.56% GLDAF Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanomaWOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that the first patient has been randomized and dosed in the IGNYTE-3 study – a glob GlobeNewswire ? 2 months ago REPL -1.56% Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024Protocol finalized for registration-directed study of RP2 in uveal melanoma with study initiation activities underway WOBURN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology GlobeNewswire ? 2 months ago REPL -1.56% Replimune Announces $100 Million Private Placement Financing - Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA filing expected in 2H 2024 - - Proceeds enable full commercial scale up to support a potential launch in 2H 2025 - WOBURN, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage b GlobeNewswire ? 4 months ago REPL -1.56% Replimune (REPL) Gains on Positive Data From Melanoma Study Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain. Zacks ? 4 months ago REPL -1.56% ALXO Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. GlobeNewswire ? 4 months ago REPL -1.56% Sector Update: Health Care Stocks Higher in Late Afternoon Trading Sector Update: Health Care Stocks Higher in Late Afternoon Trading PREMIUM MT Newswires ? 4 months ago VNDA REPL -1.56% Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat several types of cancer. The results show that one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024. All resp Benzinga ? 4 months ago REPL -1.56% Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today annou GlobeNewswire ? 4 months ago REPL -1.56% Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data from IGNYTE trial -- -- RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrates overall response rate of nearly 30 percent; planning for registration-directed trial underway -- WOBURN, Mass., June 03, 2024 (GLOBE NEWSWIRE) - GlobeNewswire ? 4 months ago REPL -1.56% Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024. The Company has two abstracts selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from GlobeNewswire ? 4 months ago REPL -1.56% Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biologics License Application (BLA) submission expected in 2H 2024 Enrollment of first patients in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in 2H 2024 Cash runway to fund operations into 2H 2026 WOBURN, Mass GlobeNewswire ? 5 months ago REPL -1.56% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return REPL S&P 500 YTD +34.64% +22.73% 1-Year -23.52% +38.58% 3-Year -60.92% +29.05%
